bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer

Apakama, Ike; Robinson, M. R. G.; Walter, NM; Charlton, R.; Royds, JA; Fuller, C. L.; Neal, DE; Hamdy, Freddie C.

doi:10.1038/bjc.1996.526

Cited by 123 publications

(72 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For that reason both BCL-2 expression and proliferative rate were quantitated in immunoreactivity`hot spot' areas of the tumours. In accordance with previous studies examining tumours of various stages 30,31 our results showed that approximately half of the tumours expressed BCL-2 protein. In general, BCL-2 has been found to be expressed in at most one out of four clinically localized tumours.…”

Section: Discussionsupporting

confidence: 93%

Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly

Borre

Srausbol-Gron

Nostrom

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The prognostic value of BCL-2 expression, solely and combined with Ki-67 expression, was determined in prostate cancer patients followed expectantly. Furthermore, associations with well established prognostic markers were tested. Formalin ®xed, paraf®n-embedded tumour tissue obtained at diagnosis was immunohistochemically investigated in 221 patients with a 15 y median followup time. BCL-2 protein was expressed in 114 (52%) tumours and was signi®cantly associated with tumour stage (P 0.01). The prognostic value of BCL-2 expression was signi®cant, using both disease-speci®c (P 0.0015) and overall survival (P 0.005) as endpoint. Patients with a combined BCL-2 negative/Ki-67`low' tumour had the most favourable prognosis. This combined BCL-2/Ki-67 variable was of independently prognostic value in both the entire population (P 0.0001) and in the clinically localized subpopulation (P 0.035).

show abstract

Section: Discussionsupporting

confidence: 93%

Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly

Borre

Srausbol-Gron

Nostrom

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Bcl-2 is overexpressed in a variety of human cancers, including prostate cancer (4)(5)(6). In prostate cancer, overexpression of bcl-2 is associated with prostate tumor aggressiveness (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

“…In prostate cancer, overexpression of bcl-2 is associated with prostate tumor aggressiveness (7)(8)(9). Moreover, Bcl-2 protein is increased in the majority of tumors from men with androgen-refractory disease and is associated with resistance to androgen deprivation and RT (4,6,(10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Antisense Bcl-2 sensitizes prostate cancer cells to radiation

Hachem

Pollack

2005

Prostate

View full text Add to dashboard Cite

BACKGROUND-Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness. We hypothesized that Bcl-2 has a role in prostate cancer radiation (RT) response. The relationship of Bcl-2 expression in four prostate cancer cell lines, and the effect of modulating expression with a Bcl-2 antisense oligonucleotide (G3139, Genasense ® , oblimersen sodium, Genta Incorporated), to RT was examined.

show abstract

“…The BCL2 oncoprotein inhibits apoptosis and is overexpressed by many tumours including breast (Hellemans et al, 1995), colon (Bronner et al, 1995), prostate (Krajewska et al, 1996) and tumours of the head and neck (Gallo et al, 1999). By virtue of its biological activity, it may be associated with a poor prognosis, with resistance to current treatment modalities including radiotherapy, for example, in cervical (Harima et al, 1998) and prostate cancer (Apakama et al, 1996). The data available to date, describing the role played by BCL2 in transitional cell carcinoma (TCC) of the bladder, have been both limited and conflicting, with some studies showing an association with a lower tumour grade (King et al, 1996) and less aggressive phenotype (Shiina et al, 1996).…”

mentioning

confidence: 99%

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

et al. 2003

View full text Add to dashboard Cite

The purpose of the study was to investigate the effects of expression of a range of genes involved in apoptosis on outcome in bladder cancer. Immunohistochemistry was used to examine expression of BCL2, BAX, P53, CD40 and CD40L in archival tissues of patients In conclusion, it was seen that overexpressions of BAX and CD40L are prognostic of better survival in TCC of the bladder. Our results also raise the possibility of the future development of CD40-and CD40 ligand-based immunotherapy for bladder cancer. This study links proapoptotic and antiapoptotic markers to overall survival.

show abstract

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer

Cited by 123 publications

References 22 publications

Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly

Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly

Antisense Bcl-2 sensitizes prostate cancer cells to radiation

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

Contact Info

Product

Resources

About